Clinical trials: Bone Marrow
Chronic Myelogenous Leukemia
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
- Trial name
- NCT03216070
- Testing
- Dasatinib 50 MG
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
- Trial name
- NCT01085656
- Testing
- OXi4503
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Florida
Paroxysmal Nocturnal Haemoglobinuria
Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal haemaoglobinuria (PNH) is a rare disease which results in breakdown of the red blood cells and bone marrow failure. It is associated with an increased risk of blood clots.
- Trial name
- NCT01020188
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- King's College Hospital NHS Trust
Chronic Myeloid Leukemia (CML)
Second STOP After Pioglitazone Priming in CML Patients
Single-center study, prospective, phase II trial. The study objectives are : To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI…
- Trial name
- PIO2STOP (NCT02889003)
- Testing
- Pioglitazone + TKI
- Where
- 6 sites in France
- Volunteers
- 26 people
- Sponsor
- Versailles Hospital
Chronic Phase Chronic Myelogenous Leukemia
Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor
The aim of the study is to assesse the levels of various biomarkers, specifically interleukin (IL)-6, platelet-derived microparticles (PDMPs), 11, 12 soluble vascular cell adhesion molecule 1 (sVCAM-1), transforming growth factor…
- Trial name
- NCT03907670
- Volunteers
- 45 people
- Sponsor
- Assiut University
Osteoporosis, Osteoarthritis
OSTEOMICS: Identifying Regulators of Bone Homeostasis
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity.
- Conditions
- Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
- Trial name
- OSTEOMICS (NCT05732870)
- Testing
- Relevant orthopaedic surgery
- Where
- 8 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Relation Therapeutics
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative…
- Conditions
- Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma
- Trial name
- NCT05515029
- Testing
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- Where
- Russia
- Volunteers
- 56 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
DTGM belongs to a new generation of drugs designed to target leukemic cells. To achieve this, DTGM takes advantage of the ability of naturally-produced growth factor (GM, granulocyte-macrophage stimulating factor) to deliver a…
- Trial name
- NCT00074750
- Testing
- DTGM
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to…
- Trial name
- NCT00441168
- Testing
- adriamycin, bortezomib, dexamethasone
- Where
- 16 sites in Croatia, Germany and 5 more
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag International NV
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q)
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT02666950
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Delirium, Cancer
Implementation of a Delirium Screening
The purpose of this project is to improve patient outcomes in individuals affected by cancer, through the implementation of a delirium screening and treatment protocol in the ICU setting.
- Conditions
- Delirium, Cancer, Bone Marrow Ablation
- Trial name
- NCT03360474
- Testing
- Delirium Screen
- Sponsor
- University of Miami
Polycythemia Vera (PV), Myelofibrosis (MF)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and…
- Conditions
- Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
- Trial name
- NCT07469891
- Testing
- PRT12396
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Prelude Therapeutics Incorporated
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Amyotrophic Lateral Sclerosis
Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis
A Phase I, single center, prospective, non-randomized, open label, safety/efficacy study of the infusion of autologous bone marrow-derived stem cells, in 6 patients with Amyotrophic Lateral Sclerosis according to established…
- Trial name
- ALS (NCT01082653)
- Testing
- autologous bone marrow-derived stem cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- TCA Cellular Therapy
Leukemia, Hodgkins Disease
Blood Samples to Evaluate Biomarkers of Donor Chimerism
We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants.
- Conditions
- Leukemia, Hodgkins Disease, Non-hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT00764829
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute
Phase I, Dose Escalation Study of Decitabine
Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML).
- Conditions
- Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute, Hematopoetic Myelodysplasia
- Trial name
- NCT02264873
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Severe Aplastic Anemia, Cyclophosphamide Reduced-dose
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH)…
- Conditions
- Severe Aplastic Anemia, Cyclophosphamide Reduced-dose, Immunosuppressive Therapy
- Trial name
- hypo-CASH (NCT06695741)
- Testing
- Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
Cytokine-induced killer ( CIK ) cells have been shown by our lab to be cytolytic against both autologous and allogeneic acute myeloid leukemia ( AML ) cells.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- alloCIK (NCT00460694)
- Testing
- infusion of allogeneic CIK cells
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- Singapore General Hospital
Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation
Impact of Yoga and Gentle Massage Practices on Symptom Management in Patients Undergoing HSCT
This project aims to observe the impact of yoga and gentle massage practices on symptom management in patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) at the Israelite Albert Einstein Hospital.
- Trial name
- Yoga (NCT06118853)
- Testing
- yoga or gentle massage plus standard treatment for HSCT
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Hospital Israelita Albert Einstein
Myelodysplastic Syndromes
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
- Trial name
- NCT06113302
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.